Navigation Links
nContact Announces Initiation of Clinical Trials for the Treatment of Paroxysmal Atrial Fibrillation Utilizing New Convergent Ablation Procedure
Date:12/1/2009

MORRISVILLE, N.C., Dec. 1 /PRNewswire/ -- nContact Surgical, Inc. ("nContact"), a leader in the investigation of devices for minimally-invasive treatment for heart conditions, today announced the initiation of a feasibility clinical trial designed to evaluate the safety and efficacy of a combined surgical and catheter procedure, the convergent procedure, for the treatment of symptomatic paroxysmal atrial fibrillation (AF). This prospective, feasibility study will enroll patients at study sites across the United States.

"We designed this study to include paroxysmal patients with enlarged hearts, who historically have been more difficult to treat with catheter ablation in a single procedure," said John P. Funkhouser, President and CEO of nContact. "The uniqueness of the convergent procedure is that lesions can be created on all areas of the heart through a closed chest endoscopic approach, without lung deflation, and while the heart is beating. It is hoped that the combination of surgical and electrophysiology techniques will enhance physicians' capability to ultimately treat all AF patients in a single procedure."

The study utilizes the nContact Numeris®( )- AF Guided Coagulation System with VisiTrax® along with a commercially available ablation catheter, the Biosense Webster NaviStar®( )ThermoCool® Catheter. The combination of devices creates a standard, bi-atrial lesion pattern to block electrical signals that cause AF. In addition, electrophysiologists have the capability to diagnostically ensure the lesion pattern is complete with pulmonary vein isolation. "We look forward to investigating this collaborative, interdisciplinary approach for the treatment of atrial fibrillation in patients with larger atria," said Dr. Rodney Horton, Principal Investigator at St. David's Medical Center in Austin, Texas.

About nContact Surgical, Inc.

nContact is a medical device company founded in 2005 with the company mission to develop devices for the endoscopic treatment of arrhythmias, including atrial fibrillation (AF). The Numeris® Coagulation System with VisiTrax® is based on the unique integration of suction, perfusion, and RF energy to ensure the creation of visible, non-conductive, bi-atrial epicardial lesions on a beating heart.

To date, The Numeris Coagulation System with VisiTrax is indicated for the coagulation of cardiac tissue in the United States. nContact has initiated clinical studies for the treatment of AF in both open and closed chest procedures. The Numeris( )Coagulation System with VisiTrax has CE Mark approval in Europe for the specific indication for the coagulation of cardiac tissue for the treatment of atrial fibrillation and atrial flutter.


nContact, Inc.
1001 Aviation Parkway, Ste 400
Morrisville, NC  27560
T (919) 466-9810
F (919) 466-9811

Media Contacts
Angela Moser
nContact Surgical, Inc.
amoser@ncontactsurgical.com

Scott Lerman
The Ruth Group
T (646) 536-7013
slerman@theruthgroup.com

SOURCE nContact Surgical, Inc.


'/>"/>
SOURCE nContact Surgical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. nContact Announces Initiation of Clinical Trials for the Treatment of Atrial Fibrillation in Open-Chest Procedures
2. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
3. Acuo Technologies Announces Patent for Asset Communication Format Within a Computer Network
4. Heska Announces Supply Agreement With Roche Diagnostics
5. Swissray International Announces New Ownership
6. NuVasive Announces Conference Call and Webcast Regarding Reimbursement
7. Infinite Mind Announces the Launch of a New Online Vision Therapy Program eyeQ
8. Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting
9. HealthWarehouse.com, Inc. Announces Third Quarter Financial Results; Revenues, Margins, and Orders Shipped Increase Over Third Quarter 2008
10. West Announces Management Change
11. Ligon Discovery Announces Appointment of Errol B. De Souza as Executive Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... TAIPEI, Taiwan , March 28, 2017 /PRNewswire/ ... medical device company, is pleased to announce ... Series A investment of Panther Orthopedics, Inc., a ... pioneering innovative dynamic fixation solutions for orthopedic extremity ... market continues to expand rapidly, primarily due to ...
(Date:3/27/2017)... March 27, 2017 The National University ... and data analytics company, signed a Memorandum of ... healthcare delivery in the region. ... Health Research and Technology (BIGHEART) at NUS and ... topics related to healthcare IT and medical device ...
(Date:3/27/2017)... , March 27, 2017 ... better understand Eli Lilly and its partnering interests and activities ... 2010 report provides an in-depth insight into the partnering activity ... On demand company reports are prepared upon purchase to ... company data. The report will be delivered in ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... Award-winning ... will begin serving as new board chair for Orange County health care system ... the remainder of soon-to-be former chair Mark Refowitz’s term, which runs through June ...
(Date:3/28/2017)... ... March 28, 2017 , ... In its ... Success website has recently developed and published an informational resource that addresses frequently ... based on common inquiries the site’s team of third party administrator (TPA) contributors ...
(Date:3/28/2017)... Santa Monica, CA (PRWEB) , ... March 28, ... ... expert, Dr. Carson Liu of SkyLex Advanced Surgical, Inc. is thrilled to offer ... newest gastric balloon procedure, and this procedure adds to SkyLex Advanced Surgical’s ...
(Date:3/28/2017)... ... ... skin is a common and unwelcomed occurrence in people of all ages, genders and ethnicities. ... the discussion of dealing with excess skin oil. “Oily skin is a challenge to many ... help remove the oily shine while keeping the skin fresh and clean,” says Dr. Au. ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who have sleep ... apnea treatment, with or without a referral. Sleep apnea is often left untreated because ... sleepiness, morning headaches and chronic snoring. , Dr. Braasch seeks to raise awareness ...
Breaking Medicine News(10 mins):